HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption
Early-phase HIV remission ("cure") trials aim to test interventions developed to eradicate HIV or to sustainably control HIV without antiretroviral treatment (ART). Many remission trials include analytic treatment interruption (ATI) to evaluate interventions, which increases the risk to pa...
Saved in:
Main Authors: | Eunice Akinyi Okumu (Author), Gail E. Henderson (Author), Carol Golin (Author), Kriste Kuczynski (Author), Nuchanart Q. Ormsby (Author), Holly L. Peay (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corrigendum to "HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption" [J Virus Erad 9 (2) (June 2023) 100331]
by: Eunice Akinyi Okumu, et al.
Published: (2023) -
What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent
by: Holly L. Peay, et al.
Published: (2015) -
53 Perceptions of HIV remission ("cure") trials and trial intentions among potential participants treated in acute HIV infection
by: H. Peay, et al.
Published: (2016) -
Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk
by: Karine Dubé, et al.
Published: (2024) -
How do HIV cure trial researchers respond to an embedded social science study?
by: H. Peay, et al.
Published: (2019)